Marker Therapeutics Inc 뉴스 - MRKR | 주식 나스닥

개인 투자자를 위한 전문가급 도구.

프리미엄

Form S-3 - Registration statement under Securities Act of 1933

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...

Form 8-K - Current report

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated...

Form 8-K - Current report

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

CorsairNavigator20 1 시간 전

According to the jmp conference Dr Vera is going to be talking to registered investors. Anybody on this site going to have a chat with him

👍️0

learningcurve2020 8 시간 전

Never be embarrased for biotech management because they always seem to do just fine for themselves. It's the silent shareholders who deserve to be embarrassed.

CorsairNavigator20 24 시간 전

One would hope not. I could feel embarrassed for him if that is the case. Waiting to see if he will talk about trends in the data.

👍️ 2

learningcurve2020 1 일 전

Hallelujah! Better not be just three trial patients.

👍️0

jobynimble 1 일 전

https://www.globenewswire.com/news-release/2024/11/26/2987657/0/en/Marker-Therapeutics-to-Present-at-the-Citizens-JMP-Hematology-and-Oncology-Summit.html

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
November 26, 2024 11:00 ET
| Source: Marker Therapeutics

HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit. This investor event will be held virtually on December 2, 2024.

Dr. Vera will present an overview of Marker’s technology and clinical developments on Monday, December 2, 2024, at 11 AM EST.

Click above link for full release…

👍️ 1

ShadowHaven59 1 일 전

Could it be the conference on Monday, why they were taking extra time to prepare the final data? Hopefully they release news on Monday. let’s see a run up on the stock price before the conference.

👍️ 2

learningcurve2020 1 일 전

Yup, Vera is still on their board. Guess he couldn't sell a Marker takeover. Anyone here ever ask him about it?

https://www.allovir.com/our-people/juan-f-vera-md

👍️0

ShadowHaven59 2 일 전

The company responded to me on 11/12 and 11/15 hopefully they’re trying to get better. I just like that the same information the analyst received, so did I.

👍️0

learningcurve2020 2 일 전

There's that "Runway" language again. AlloVir cut their staff and are using their remaining $100M for a new drug in a new indication instead of simply taking over Marker where they could've put their off the shelf T-cell knowledge to good use.

>>The merged company is expected to have $100 million in the bank, which is set to pave a cash runway into the final months of 2026. AlloVir’s stockholders will own 25.05% of the resulting entity, with Kalaris’ stockholders owning the other 74.95%.

https://www.fiercebiotech.com/biotech/struggling-allovir-finds-new-identity-merging-eye-disease-biotech

👍️0

learningcurve2020 2 일 전

Thanks. What were the dates on those emails?...How much time has gone by?

👍️0

learningcurve2020 2 일 전

Not important, I guess. LOL

👍️0

ShadowHaven59 3 일 전

Yes, no problem, the first email I previously spoke about was the lack of transparency from the company and keeping the shareholders in the dark about the data from all the trials. The company responded agreeing with me and said they will work on trying to be more transparent and also keeping the shareholders more up-to-date. the company said they are currently working a comprehensive data update and are looking forward to sharing this information with our investors after completion of some remaining details. we appreciate your patience. this was the same information that the company told the analyst. The second email was just basically asking the CEO and upper management to buy shares in the open market if they believe in the company and the platform. Maria responded by thanking me and she said that she will forward the message to upper management.

👍️0

CorsairNavigator20 3 일 전

Do you care to share your discussions with them

👍️ 1

ShadowHaven59 4 일 전

I’ve noticed a change in the frequency of responses from the company lately. in the last two years, I have never received a response, but in the last two months, I have received a response from my last two emails to the company, not sure it means anything, but I thought I would just post it in the chat room anyway. thank you everyone for your valuable information.

👍️0

learningcurve2020 4 일 전

Have you ever asked them why they don't address their shareholders on quarterly calls /Q&A but instead seem to rely on you to communicate?

microcapbiotech 5 일 전

Interesting cancer article. "Groundbreaking clinical trial cures cancer in 100% of patients."
https://www.msn.com/en-us/health/other/groundbreaking-clinical-trial-cures-cancer-in-100-of-patients/ar-AA1uqFJg?ocid=msedgdhp&pc=U531&cvid=be9d60cda7174620ee78a7879d0f9022&ei=45
Which brings up a question that I asked about 2 years ago, WHY doesn't MRKR use their Multi TAA, (now called MAR) ALONG WITH a checkpoint inhibitor that blocks the PD-1 protein on T-cells? Never got an answer to that.

👍️ 1

Flyingj 5 일 전

Anybody know where the 1.92 million in sales came from this quarter? Is part of it right to try patients

👍️0

Phantom Lord 5 일 전

Very tight lipped on the data. Just that they are encouraged by what they are seeing but I would expect them to say that regardless of what is happening with the trial.

learningcurve2020 5 일 전

I never imagined a one trick pony biotech could put out a fresh 10q and forget to update their shareholders on the trial. Seems impossible.

👍️0

CorsairNavigator20 5 일 전

Were you able to ask about data subsets. My line of conjecture would be they saw a commonality in patients with good outcomes, approached the FDA to narrow the indication and had to increase sample size. Only positive reason why it's taking forever. Yes that will really change the future of this company. Just trying to keep a positive spin. Were you able to get them to talk data at all or tell you it is going to be the greatest thing since sliced bread.

👍️0

learningcurve2020 5 일 전

If the treatment is showing good efficacy it should be a cinch to enroll such small numbers. So it begs the question, why would they sabotage their own company?

👍️0

learningcurve2020 5 일 전

Not a good sign for Marker, IMO. Should've been Marker not Kalaris. Nobody wants to talk about here, of course.

https://www.biopharmadive.com/news/allovir-kalaris-reverse-merger-retina-diseases/732385/

👍 1

Phantom Lord 5 일 전

This is only partly true. They stopped the MT401 AML PII trial to refocus their efforts in AML on the OTS version of MT401. That trial was supposed to start by the end of this year but true to form the company blew right by their own timeframe. It's supposed to start first half of next year now, IIRC. Who really knows if this will end up being the right decision or not.

👍️ 2

Phantom Lord 5 일 전

I'm not worried about bad data. I'm worried that management is making poor decisions in their execution of the release. Ah86 hit the nail on the head. Their problem has always been trickling out data on an inconsequential number of patients. It's great to see the CRs but when the total number of patients you're reporting on is 3, no one is going to care. They need a bigger number. I believe they know this but in my communications with the company they are very reluctant to share the enrollment numbers. That worries me. Originally the trial was supposed to enroll 37 patients. No reason it should not be fully enrolled by now at 37 patients. That being said, back in May the enrollment on clinicaltrials.gov was increased to 79. Take with that what you will. Basically, the company needs data on more patients. They gave us the data on the initial 3 as a "tease" or indicator of how the trial started but the next data release better be at least 30 patients. There is no excuse for anything less than that.

👍️ 2

ah86 5 일 전

oh i'm not missing a thing except that i'm dumbfounded that a bunch of folks would be pessimistic having sunk a ton of money in an investment.
Talk about paradox, oh my!
An alien, if given the same facts, would bet that these folks are confident of success.

👍️0

learningcurve2020 5 일 전

The market cap is now that of a promising in vitro experiment.

👍️0

Buckboard 5 일 전

Thanks. The thing you are missing is many of us on here would NOT walk away "with a few bucks" selling now. We're already down a ton and would lock in big losses. My theory is hope for the best because biggest losses already in even if they close shop. I am a pessimist like B Franklin so have no big hopes here.

👍️0

learningcurve2020 5 일 전

Shrugs.

👍️0

learningcurve2020 5 일 전

Already in penny stock land with a horrible $25M market cap. It's the small amount of shares outstanding thanks to the reverse split that's throwing you off.

👍️0

microcapbiotech 6 일 전

That definition is obvious and simple for even the most simple to comprehend. Bad data is the kind of data that gets trials CANCELED like the AML trials were.

👍️0

ah86 6 일 전

Yes, you're wrong on some fronts. This is an open label trial. You can see failure from across the Atlantic. No company as is the case with this one, can have 'bad data' and put it in the fridge.
Patience is key here. Just over 3 bucks. You may walk away with some $$ if you sell now, though I don't know your avg cost per share. But for those that are impatient, they should pray N is greater than 10 otherwise you're back to pennystock land. The stuff works but on just 3 people is apparently equivalent to 'bad data'
If they post at minimum similar results on a greater number and you may call yourself a genius for picking this ticker.

👍️ 1

ah86 6 일 전

Define bad data,and you'll answer yourself.

👍️0

learningcurve2020 6 일 전

2029

👍️0

Buckboard 6 일 전

I may be wrong about this and PL will definitely know but it was my understanding that if they had the data collected and it was bad, they had to release that info within a few days. Otherwise, people would be still buying stock while the company withheld bad news.

👍️ 1

microcapbiotech 6 일 전

This company never produced bad data?? Is that why the AML trials were canceled?? because they produced good AML data??
I guess good data is why the website went from having several trials going to just one trial now.

👍️0

ah86 6 일 전

Allow me. The data isn't bad. This company has never produced bad data. Period.
The problem has always been? wait for it, drum roll - N
You can't get heads to turn with N being 2 or 3.
And that exactly, without doubt, is what is taking this so long. And failing to provide enough of N will cause this to slip like it hit a banana peel.

👍️ 1

ShadowHaven59 6 일 전

Phantom Lord, what is the latest date you would give this company to show the data before you would start thinking that the data is bad? thank you.

👍️0

learningcurve2020 1 주 전

So, this Marker board member pays Marker cash to buyout their manufacturing start up facility, then he becomes a contractor where Marker pays him millions quarterly for what exactly we're not sure. The company oddly cancels all their agreements to raise cash. All as MRKR provides no update on the progress of their one trial. Do I have that right so far?

https://markertherapeutics.com/our-company/board-of-directors/

👍 1

Phantom Lord 1 주 전

Love that ignore button, lol

👍️ 5 🫣 1

ah86 1 주 전

I found the ignore button. Such a blessing!

👍️0

learningcurve2020 1 주 전

I wouldn't worry about under or over at this point, I'd worry about stealing your IP, assuming you're a shareholder, of course.

👍️0

ShadowHaven59 1 주 전

For what it’s worth, I emailed the company, Stating if upper management believes in the platform. They should buy some shares on the open market as a sign of confidence for the market and shareholders. I doubt anything will happen, but hey you never know. I can’t tell if the shares are under priced or overvalued. Lol.

👍️0

learningcurve2020 1 주 전

You mean when he allegedly talks to managment? Don't you think a normal shareholder would want to comment on that last 10Q having no update on the trial?

🚫 2 ❌️ 2

travayl 1 주 전

Phantom generally posts when he has information to share.

👋 1 👍️ 1

learningcurve2020 1 주 전

Phantom goes silent, of course.

🙈 1 🙉 1

learningcurve2020 2 주 전

Because I do believe in this T cell tech, I'm actually more worried they're trying to slip it out the back door as we wait for something that may never come. Feels that way.

👍️0

learningcurve2020 2 주 전

I saw that. But I'm not sure 34% is bad in biotech?? LOL. It's more about what you bet heavy on. Seems like maybe 5% of biotech investors actually do well. It's a racket, IMO.

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Marker Therapeutics Inc (MRKR)

개인 투자자를 위한 전문가급 도구.

MRKR 뉴스

Form S-3 - Registration statement under Securities Act of 1933

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Form 8-K - Current report

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

MRKR Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Marker Therapeutics Inc (MRKR) 뉴스

Marker Therapeutics Inc (MRKR)

개인 투자자를 위한 전문가급 도구.

MRKR 뉴스

Form S-3 - Registration statement under Securities Act of 1933

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Form 8-K - Current report

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

MRKR Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기